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Abstract: The present investigation reports on the use of problem solving therapy (PST) 
to treat depression in an 83-year-old woman with Parkinson’s disease (PD) and concurrent 
mild cognitive impairment (MCI). A neuropsychological evaluation was conducted prior 
to the intervention and the patient demonstrated mild deﬁ  cits of executive functioning 
and memory. The PST treatment consisted of 12 one-hour sessions that occurred weekly. 
Depressive symptoms were evaluated using the Hamilton Depression Rating scale and the 
Montgomery-Asberg Depression rating scale. At a post-treatment assessment (week 12), 
clinician assessment indicated that the client no longer met criteria for MDD. Weekly depres-
sion severity ratings showed signiﬁ  cant reduction in severity of depressive symptoms over 
12 weeks. Results at 1-month and 6-month follow-up demonstrated that the therapeutic gains 
were not only maintained, but that the client continued to improve. These results suggest 
that PST may be an effective treatment for the treatment of depression for individuals with 
a PD and concurrent MCI.
Keywords: problem solving therapy, psychotherapy, mild cognitive impairment, executive 
dysfunction, memory, Parkinson’s disease, depression, geriatric
Introduction
Depression commonly co-occurs with Parkinson’s disease (PD) with prevalence 
rates of 20%–50% based on community samples (Errea and Ara 1999; Schrag et al 
2001, 2002). The high comorbidity between depression and PD has been attributed 
to both neurodegenerative changes in the mesocorticolimbic pathway in the frontal 
striatal regions of the brain (Robinson et al 1999) and the affective distress related to 
functional impairment (Brown and Jahanshahi 1995). Depression in PD patients is a 
signiﬁ  cant health concern that has been linked to increased disability and decreased 
quality of life (Gotham et al 1986; Starkstein et al 1990; Karlsen et al 1999; Kanner and 
Barry 2003; Martinez-Martin et al 2003; Schrag 2004) as well as increased mortality 
(Hughes et al 2004) and risk of suicide (Myslobodsky et al 2001). In addition, patient 
depression has also been shown to negatively affect PD caregivers and is commonly 
linked to caregiver depression and distress (Aarsland et al 1999; Meara et al 1999; 
Fernandez et al 2001).
Mild cognitive impairment (MCI), a syndrome referring to cognitive impairments 
that do not meet criteria for dementia (Busse et al 2003; Voisin et al 2003), is also 
common in PD, with estimates of MCI in PD clinical samples ranging from 10% to 
55% (Ostrosky-Solis 2000; Janvin et al 2003; Bosboom et al 2004; Hobson and Meara 
2004; Zakharov and Iakhno 2005). Among depressed PD patients the incidence of 
MCI is likely higher as depression can exacerbate cognitive symptoms (Uekermann 
et al 2003). The current standard of practice for treating depression among individuals Neuropsychiatric Disease and Treatment 2006:2(3) 376
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with PD is psychopharmacological intervention (Slaughter 
et al 2001; Marsh and Berk 2003; Shabnam et al 2003; 
Leentjens 2004). However, concerns regarding the efﬁ  cacy 
and safety of these medications have been raised (Shabnam 
et al 2003) and a signiﬁ  cant portion of PD patients being 
treated for depression often do not respond to one or more 
trials of pharmacotherapy (Weintraub et al 2003). Although 
there have not yet been studies investigating the effective-
ness of pharmacological interventions speciﬁ  cally for older 
PD patients with MCI, these individuals may be further at 
risk for poor and unstable response to antidepressants due to 
changes in the frontal-subcortical brain regions (Alexopoulos 
et al 2000).
Given the prevalence of depression among PD patients, 
the impact of depression on patient quality of life, and the 
potential for poor responses to pharmacotherapy, there 
is a surprising lack of research on evidence-based psy-
chotherapeutic interventions for these individuals. This 
is particularly apparent given the usefulness of psycho-
therapeutic interventions in late life depression (Areán and 
Cook 2002). Problem solving therapy (PST), in particular, 
has been shown to be effective for the treatment of depres-
sion in older adults (Areán et al 1993), older adults with 
mild cognitive impairment (Alexopoulos et al 2003), and 
depressed medically frail elders (Mynors-Wallis et al 
2000). This case study is presented to raise awareness of 
the need to develop evidence-based psychotherapeutic 
interventions for depression among individuals with PD 
and MCI.
The case: PK
Presenting complaint
The patient is an 83-year-old Caucasian woman with PD 
who was diagnosed with major depressive disorder (MDD) 
based on a structured clinical interview for the Diagnostic and 
Statistical Manual of Mental Disorders-IV (APA 1994). The 
onset of depressive symptoms began approximately 5 years 
ago with gradual worsening over this interval. Suicidal 
ideation was denied and the patient had no prior history of 
treatment for depression. The patient is non-ambulatory and 
has resided in a long-term skilled nursing home since 2003. 
The patient endorsed mild memory difﬁ  culties; other cogni-
tive difﬁ  culties were denied.
Medical history
The patient’s medical history was signiﬁ  cant for PD and 
hypertension. Recent head imaging (CT) indicated a 
generalized prominence of the ventricles and sulci consistent 
with generalized atrophy. Additionally, areas of low 
attenuation were reported in periventricular and subcortical 
areas without evidence of cortical infarction, hemorrhage or 
mass lesion. Her medications included: docusate (250 mg), 
prilosec (20 mg), hydralazine (50 mg), divalproex sodium 
500 mg, carbidopa–levodopa (25 mg/100 mg), gabapentin 
(300 mg), furosemide (40 mg).
Cognitive assessment
The patient participated in a neuropsychological screening 
assessment prior to treatment as part of her intake evalua-
tion. The cognitive evaluation consisted of the following 
measures: the Mini-Mental State Exam (Folstein et al 1975), 
the Wisconsin Card Sorting Test-64 Computer Version 
2 (WCST) (PAR 2000), the Stroop Color and Word Test 
(Stoelting 2002), the Hopkins Verbal Learning Test - Revised 
(HVLT-R) (Brandt and Benedict 2001), and the Dementia 
Rating Scale-2 (DRS-2) (Mattis 2004). The results of this 
screening evaluation (Table 1) indicate that the patient 
demonstrated relative strengths in attention, constructional 
ability, and conceptualization ability. Mild impairments were 
observed on measures of executive function and memory. 
These observed cognitive deﬁ  cits, in conjunction with a 
review of functional status, were consistent with a diagnosis 
of mild cognitive impairment. They did not warrant a DSM-IV 
diagnosis of dementia since these cognitive deﬁ  cits were 
mild and did not signiﬁ  cantly impair social functioning. 
Nonetheless, these impairments had the potential of limiting 
the effectiveness of psychotherapy, as psychotherapy 
Table 1 Results of cognitive screening evaluation
Measure %ile
Mini Mental State Exam 25/30a
Dementia Rating Scale -2
 Attention 19–28
 Initiation/perseveration 6–10
 Construction 41–59
 Conceptualization 19–28
 Memory 6–10
  DRS total score 6–10
Stroop Test Color-Word Score 3
Wisconsin Card Sorting Test (64 Card)
 Categories  completed 6–10
 Total  errors 4
 Perseverative  errors 1
Hopkins Verbal Learning Test
 Acquisition 1
  Long delay free recall 7
  Long delay cued recall 25
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involves learning new skill sets, remembering information 
from previous sessions, problem solving, and planning 
abilities.
Measures of depression severity
The Hamilton Depression Rating Scale (Hamilton 1960) is a 
17-item instrument yielding scores from 0 to 34; high scores 
indicate greater severity of depression. The HDRS is an 
interviewer-rated instrument shown to be sensitive to change 
over time and has been shown to be a be a valid measure of 
depressive symptoms with Parkinson’s patients (Leentjens 
et al 2000; Burn 2002).
The Montgomery Asberg Depression Rating Scale 
(MADRS) (Montgomery and Asberg 1979) is a com-
monly used measure of severity of depressive symptoms 
(Zimmerman et al 2004) which has been validated with 
Parkinson’s patients (Leentjens et al 2000; Burn 2002).
Intervention
The psychotherapeutic intervention consisted of 12 one-hour 
sessions with a licensed therapist following a structured 
PST protocol. The patient did not utilize antidepres-
sant medications during the course of this treatment or 
the subsequent follow-up period. PST for older adults 
with executive dysfunction was developed by Areán 
(Alexopoulos et al 2003) to speciﬁ  cally accommodate 
cognitive problems commonly experienced among older 
depressed adults. The premise of the intervention is that 
depression is caused, in part, by difﬁ  culty coping with 
psychosocial problems (Nezu and Perri 1989). The therapy 
is designed to help individuals overcome depression by 
teaching them a systematic way of solving these problems 
while accommodating mild cognitive impairments. 
The major components of the therapy include 8 stages: 
1) Selecting and defining problems, 2) Establishing 
realistic goals, 3) Generating alternative solutions to meet 
stated goals, 4) Implementing decision making guidelines, 
5) Evaluating and choosing solutions, 6) Implementing 
the preferred solution, 7) Evaluating the outcome, and 
8) Activity scheduling.
During the ﬁ  rst session of PST with PK, the therapist 
explained the rationale for PST and emphasized the relation-
ship between depression and problem solving skills. During 
this session, the therapist and patient created an extensive 
list of psychosocial problems the patient was experienc-
ing. PK’s initial problem list consisted of problems such 
as “I feel lonely,” “I’m bored,” “I’m too dependent on 
others”. The therapist then helped the patient to select and 
deﬁ  ne her most signiﬁ  cant problem (“worrying about my 
health”). For the remainder of the session this problem 
was focused on as a way of introducing the remaining 
7 stages–steps of PST. After deﬁ  ning her chosen problem 
and establishing realistic goals, the patient was encour-
aged to generate alternative solutions and implement 
decision-making guidelines to choose her best solution. 
In the subsequent session, PK was able to report that she 
was able to implement and evaluate the outcome of her 
preferred solution.
As therapy progressed PK became more familiar with 
the steps of PST and reported that she felt progressively 
“more in control” of her health. By session #7, she reported 
that she was able to apply her problem solving approach 
independently in many situations, such as ﬁ  nding a safe 
and effective method of transferring herself from her 
wheelchair to the toilet in order to void independently, as 
well as identifying the need for, and steps to obtain, an 
ampliﬁ  ed phone. She utilized these successes to develop 
increased activity planning, such as participating more 
consistently in daily activities offered at her residential 
facility including yoga and art classes, and reconnecting 
with friends by phone.
PK completed 12 sessions of PST and at the conclusion 
of her treatment she no longer met criteria for major 
depressive disorder based on DSM-IV criteria (assessed 
by a licensed therapist with a structured clinical inter-
view). Assessments of depression severity at 1-month and 
6-months post treatment indicated treatment gains were 
maintained. Depression severity scores for the intervention 
and follow-up period are shown in Figure 1. Qualitatively, 
PK attributed improvements in mood status to learning 
that even “big problems can be broken down into more 
workable pieces”.
Discussion
Given the prevalence of MDD and MCI in individuals with 
PD, there is a surprising lack of evidence-based research 
on psychotherapeutic interventions for these individuals. 
This is particularly relevant due to concerns regarding 
the efﬁ  cacy and safety of pharmacological interventions 
for MDD among individuals with PD, and the efﬁ  cacy of 
PST in the treatment of depression in older adults who are 
medically frail and/or have mild cognitive impairments. We 
presented this case study to raise awareness that PST may 
be an effective treatment for MDD with PD and concurrent 
MCI. Additionally, although formal measures of disability 
were not administered, PK reported that PST had the added Neuropsychiatric Disease and Treatment 2006:2(3) 378
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benefit of minimizing disability; a finding not traditionally 
associated with pharmacological interventions alone.
Conclusions
This case study suggests that PST holds promise for treating 
depression among PD patients with MCI and may also 
be helpful in decreasing disability for these individuals. 
Randomized clinical trials should be conducted to evaluate 
the effectiveness of structured psychotherapeutic inter-
ventions for the treatment of MDD among patients with 
PD and MCI to determine the generalizability of these 
ﬁ  ndings.
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Figure 1 Depression severity for 12 weeks of therapy and 6-month follow-up
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